Analysis and clinical characteristics of acute myeloid leukemia developing with prior or concurrent tumors in non cyto- or radiotherapy exposure patients in a single center

References

• Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018 Nov;68(6):394–424. doi:10.3322/caac.21492.
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. Ca A cancer J clin. 2020;70(1):7–30. doi:10.3322/caac.21590.
   PubMed Web of Science ®Google Scholar
• Xia C, Dong X, Li H, et al. Cancer statistics in China and United States, 2022: profiles, trends, and determinants. Chin Med J (Engl). 2022 Feb 9;135(5):584–590. doi:10.1097/CM9.0000000000002108.
   PubMed Web of Science ®Google Scholar
• Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the world health organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391–2405. doi:10.1182/blood-2016-03-643544.
   PubMed Web of Science ®Google Scholar
• Björkholm M, Hultcrantz M, Derolf ÅR. Leukemic transformation in myeloproliferative neoplasms: therapy-related or unrelated?. Best Pract Res Clin Haematol. 2014;27:141–153. doi:10.1016/j.beha.2014.07.003.
   PubMed Web of Science ®Google Scholar
• Kayser S, Döhner K, Krauter J, et al. The impact of therapy-related acute myeloid leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AML. Blood. 2011;117:2137–2145. doi:10.1182/blood-2010-08-301713.
   PubMed Web of Science ®Google Scholar
• Dhakal P, Pyakuryal B, Pudasainee P, et al. Treatment strategies for therapy-related acute myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2020 Mar;20(3):147–155. doi:10.1016/j.clml.2019.12.007.
   PubMed Web of Science ®Google Scholar
• Lancet JE, Uy GL, Cortes JE, et al. CPX-351 (cytarabine and daunorubicin) liposome for injection versus conventional cytarabine plus daunorubicin in older patients with newly diagnosed secondary acute myeloid leukemia. J Clin Oncol. 2018;36:2684–2692. doi:10.1200/JCO.2017.77.6112.
   PubMed Web of Science ®Google Scholar
• Collinge E, Loron S, Larcher MV, et al. Elderly patients (Age 70 years or older) with secondary acute myeloid leukemia or acute myeloid leukemia developed concurrently to another malignant disease. Clin Lymphoma Myeloma Leuk. 2018 May;18(5):e211–e218. doi:10.1016/j.clml.2018.02.018.
   PubMed Web of Science ®Google Scholar
• Boddu PC, Kantarjian HM, Ravandi F, et al. Characteristics and outcomes of older patients with secondary acute myeloid leukemia according to treatment approach. Cancer. 2017 Aug 15;123(16):3050–3060. doi:10.1002/cncr.30704.
   PubMed Web of Science ®Google Scholar
• GranfeldtØstgård LS, Medeiros BC, Sengeløv H, et al. Epidemiology and clinical significance of secondary and therapy-related acute myeloid leukemia: A national population-based cohort study. J Clin Oncol. 2015 Nov 1;33(31):3641–3649. doi:10.1200/JCO.2014.60.0890.
   PubMed Web of Science ®Google Scholar
• Chakraborty S, Sun CL, Francisco L, et al. Accelerated telomere shortening precedes development of therapy-related myelodysplasia or acute myelogenous leukemia after autologous transplantation for lymphoma. J Clin Oncol. 2009;27:791–798. doi:10.1200/JCO.2008.17.1033.
   PubMed Web of Science ®Google Scholar
• Higuchi M, Sasaki S, Kawadoko S, et al. Epstein-Barr virus-positive diffuse large B-cell lymphoma following acute myeloid leukemia: a common clonal origin indicated by chromosomal translocation t(3;4)(p25;q21). Int J Hematol. 2015;102(4):482–487. doi:10.1007/s12185-015-1802-4.
   PubMed Web of Science ®Google Scholar
• Powell BL. Arsenic trioxide in acute promyelocytic leukemia: potion not poison. Expert Rev Anticancer Ther. 2011;11:1317–1319. doi:10.1586/era.11.128.
   PubMed Web of Science ®Google Scholar
• Lo-Coco F, Avvisati G, Vignetti M, et al. Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. N Engl J Med. 2013;369:111–121. doi:10.1056/NEJMoa1300874.
   PubMed Web of Science ®Google Scholar
• Hulegårdh E, Nilsson C, Lazarevic V, et al. Characterization and prognostic features of secondary acute myeloid leukemia in a population-based setting: a report from the Swedish Acute Leukemia Registry. Am J Hematol. 2015 Mar;90(3):208–214. doi:10.1002/ajh.23908.
   PubMed Web of Science ®Google Scholar
• Ohgami RS, Ma L, Merker JD, et al. Next-generation sequencing of acute myeloid leukemia identifies the significance of TP53, U2AF1, ASXL1, and TET2 mutations. Mod Pathol. 2015;28:706–714. doi:10.1038/modpathol.2014.160.
   PubMed Web of Science ®Google Scholar
• Devillier R, Gelsi-Boyer V, Brecqueville M, et al. Acute myeloid leukemia with myelodysplasia-related changes are characterized by a specific molecular pattern with high frequency of ASXL1 mutations. Am J Hematol. 2012;87:659–662. doi:10.1002/ajh.23211.
   PubMed Web of Science ®Google Scholar
• Lindsley RC, Mar BG, Mazzola E, et al. Acute myeloid leukemia ontogeny is defined by distinct somatic mutations. Blood. 2015 Feb 26;125(9):1367–1376. doi:10.1182/blood-2014-11-610543.
   PubMed Web of Science ®Google Scholar
• Higgins A, Shah MV. Genetic and genomic landscape of secondary and therapy-related acute myeloid leukemia. Genes (Basel). 2020 Jul 6;11(7):749, doi:10.3390/genes11070749.
   PubMed Web of Science ®Google Scholar
• Awada H, Kuzmanovic T, Kishtagari A, et al. Mutational patterns and clonal architecture of therapy-related acute myeloid Leukemia. Blood. 2019;134:1405, doi:10.1182/blood-2019-131953.
   Web of Science ®Google Scholar
• Turk S, Baesmat AS, Yılmaz A, et al. NK-cell dysfunction of acute myeloid leukemia in relation to the renin-angiotensin system and neurotransmitter genes. Open Med (Wars). 2022 Sep 20;17(1):1495–1506. doi:10.1515/med-2022-0551.
   PubMedGoogle Scholar
• Kerins MJ, Ooi A. A catalogue of somatic NRF2 gain-of-function mutations in cancer. Sci Rep. 2018 Aug 27;8(1):12846, doi:10.1038/s41598-018-31281-0.
   PubMed Web of Science ®Google Scholar
• Pillai R, Hayashi M, Zavitsanou AM, et al. Nrf2: KEAPing tumors protected. Cancer Discov. 2022 Mar 1;12(3):625–643. doi:10.1158/2159-8290.CD-21-0922.
   PubMed Web of Science ®Google Scholar
• Chu X, Zhong L, Dan W, et al. DNMT3A R882H mutation promotes acute leukemic cell survival by regulating glycolysis through the NRF2/NQO1 axis. Cell Signal. 2023 May;105:110626, doi:10.1016/j.cellsig.2023.110626.
   PubMed Web of Science ®Google Scholar
• Vachhani P, Al Yacoub R, Miller A, et al. Intensive chemotherapy vs. hypomethylating agents in older adults with newly diagnosed high-risk acute myeloid leukemia: A single center experience. Leuk Res. 2018 Dec;75:29–35. doi:10.1016/j.leukres.2018.10.011.
   PubMed Web of Science ®Google Scholar
• Maurillo L, Buccisano F, Spagnoli A, et al. Comparative analysis of azacitidine and intensive chemotherapy as front-line treatment of elderly patients with acute myeloid leukemia. Ann Hematol. 2018 Oct;97(10):1767–1774. doi:10.1007/s00277-018-3374-x.
   PubMed Web of Science ®Google Scholar
• DiNardo CD, Pratz K, Pullarkat V, et al. Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood. 2019;133:7–17. doi:10.1182/blood-2018-08-868752.
   PubMed Web of Science ®Google Scholar
• Cortes JE, Heidel FH, Hellmann A, et al. Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome. Leukemia. 2019;33:379–389. doi:10.1038/s41375-018-0312-9.
   PubMed Web of Science ®Google Scholar
• Guerra VA, DiNardo C, Konopleva M. Venetoclax-based therapies for acute myeloid leukemia. Best Pract Res Clin Haematol. 2019;32(2):145–153. doi:10.1016/j.beha.2019.05.008.
   PubMed Web of Science ®Google Scholar
• Richard-Carpentier G, DiNardo CD. Venetoclax for the treatment of newly diagnosed acute myeloid leukemia in patients who are ineligible for intensive chemotherapy. Ther Adv Hematol. 2019;10:204062071988282, doi:10.1177/2040620719882822.
   Web of Science ®Google Scholar
• Pan R, Ruvolo VR, Wei J, et al. Inhibition of Mcl-1 with the pan-Bcl-2 family inhibitor (-)BI97D6 overcomes ABT-737 resistance in acute myeloid leukemia. Blood. 2015;126:363–372. doi:10.1182/blood-2014-10-604975.
   PubMed Web of Science ®Google Scholar
• Pan R, Hogdal LJ, Benito JM, et al. Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia. Cancer Discov. 2014;4:362–375. doi:10.1158/2159-8290.CD-13-0609.
   PubMed Web of Science ®Google Scholar
• Bose P, Gandhi V, Konopleva M. Pathways and mechanisms of venetoclax resistance. Leuk Lymphoma. 2017;58:2026–2039. doi:10.1080/10428194.2017.1283032.
   PubMed Web of Science ®Google Scholar
• Yu WJ, Jia JS, Wang J, et al. Short-term efficacy of venetoclax combined with azacitidine in acute myeloid leukemia: a single-institution experience. ZhonghuaXue Ye Xue Za Zhi. 2022 Feb 14;43(2):134–140. doi:10.3760/cma.j.issn.0253-2727.2022.02.008.
   PubMedGoogle Scholar
• Wei AH, Montesinos P, Ivanov V, et al. Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial. Blood. 2020;135(24):2137–2145. doi:10.1182/blood.2020004856.
   PubMed Web of Science ®Google Scholar
• Aldoss I, Yang D, Aribi A, et al. Efficacy of the combination of venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia. Haematologica. 2018;103(9):e404–e407. doi:10.3324/haematol.2018.188094.
   PubMed Web of Science ®Google Scholar
• Tenold ME, Moskoff BN, Benjamin DJ, et al. Outcomes of adults With relapsed/refractory acute myeloid leukemia treated With venetoclax plus hypomethylating agents at a comprehensive cancer center. Front Oncol. 2021;11:649209, doi:10.3389/fonc.2021.649209.
   PubMed Web of Science ®Google Scholar
• DiNardo CD, Jonas BA, Pullarkat V, et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med. 2020;383(7):617–629. doi:10.1056/NEJMoa2012971.
   PubMed Web of Science ®Google Scholar
• DiNardo CD, Pratz KW, Letai A, et al. Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study. Lancet Oncol. 2018;19(2):216–228. doi:10.1016/S1470-2045(18)30010-X.
   PubMed Web of Science ®Google Scholar
• Largeaud L, Berard E, Bertoli S, et al. Outcome of AML patients with IDH2 mutations in real world before the era of IDH2 inhibitors. Leuk Res. 2019;81:82–87. doi:10.1016/j.leukres.2019.04.010.
   PubMed Web of Science ®Google Scholar
• Popovici-Muller J, Lemieux RM, Artin E, et al. Discovery of AG-120 (ivosidenib): a first-in-class mutant IDH1 inhibitor for the treatment of idh1 mutant cancers. ACS Med Chem Lett. 2018;9:300–305. doi:10.1021/acsmedchemlett.7b00421.
   PubMed Web of Science ®Google Scholar
• Turk S, Turk C, Akbar MW, et al. Renin angiotensin system genes are biomarkers for personalized treatment of acute myeloid leukemia with Doxorubicin as well as etoposide. PLoS One. 2020 Nov 25;15(11):e0242497, doi:10.1371/journal.pone.0242497.
   PubMed Web of Science ®Google Scholar
• Stone RM, Manley PW, Larson RA, et al. Midostaurin: its odyssey from discovery to approval for treating acute myeloid leukemia and advanced systemic mastocytosis. Blood Adv. 2018;2:444–453. doi:10.1182/bloodadvances.2017011080.
   PubMed Web of Science ®Google Scholar